Clinical Trial

Evaluating a Bidirectional Priming Intervention for Goals-of-care Communication in Oncology

Study acronym: Prime GOC
Completed
View on ClinicalTrials.gov →
Summary
This pilot study will evaluate whether an intervention aimed at hospitalized patients with advanced lung and gastrointestinal cancers can help facilitate goals-of-care (GOC) communication with their oncologists after discharge. While GOC communication is a recommended component of routine oncology care, many patients with solid cancers do not have the opportunity to talk with their oncologist about their goals and end-of-life preferences. Prior research has shown that a systematic method of prompting GOC communication with at-risk patients would address a key barrier to timely GOC communication and ensure that patients receive care that is in line with their personal preferences. This trial will enroll 80 participants, who will be randomized 1:1 to either an intervention or a control group. Participants in the intervention group will complete a short survey regarding their goals, preferences, and disease understanding. Survey responses will be shared with each participant's outpatient oncology team. Oncologists will subsequently receive a nudge in the electronic medical record reminding them of key survey responses and encouraging them to discuss them at the patient's first clinic visit after hospital discharge. The primary feasibility outcome is intervention completion rate and the primary clinical outcome is GOC documentation within 30 days of discharge in the intervention group compared to the control group.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-25; most recent amendment 2026-03-03.
Status change: Recruiting → Completed 2026-03-03
Status change: Not Yet Recruiting → Recruiting 2025-09-04
Trial Details
NCT Number NCT06955468
Lead Sponsor Abramson Cancer Center at Penn Medicine
Collaborators: Conquer Cancer Foundation
Conditions Lung Cancers, Gastrointestinal Cancers
Enrollment 40 participants
Start Date 2025-07-21
Primary Completion 2026-01-26 (estimated)
Study Completion 2026-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-04